Equities Analysts Offer Predictions for TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Taysha Gene Therapies in a research note issued on Thursday, February 27th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($0.38) for the year, up from their previous estimate of ($0.40). Cantor Fitzgerald has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Chardan Capital restated a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Finally, JMP Securities restated a "market outperform" rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $6.63.

Remove Ads

Taysha Gene Therapies Price Performance

NASDAQ TSHA traded down $0.01 on Monday, reaching $1.69. The company had a trading volume of 1,322,577 shares, compared to its average volume of 2,681,746. The stock has a market capitalization of $346.45 million, a PE ratio of 2.68 and a beta of 0.91. The firm's 50 day moving average price is $1.66 and its 200 day moving average price is $1.96. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of TSHA. Hsbc Holdings PLC boosted its stake in Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after buying an additional 8,076 shares during the period. Virtus ETF Advisers LLC boosted its stake in shares of Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company's stock worth $55,000 after purchasing an additional 9,494 shares during the period. Geode Capital Management LLC grew its holdings in Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock valued at $6,182,000 after purchasing an additional 9,591 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Taysha Gene Therapies by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after purchasing an additional 11,390 shares during the period. Finally, Creative Planning purchased a new stake in Taysha Gene Therapies in the 3rd quarter worth about $28,000. Hedge funds and other institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.